Petrovic 2012.

Study characteristics
Methods	Study design: RCT Study grouping: parallel‐group
Participants	Baseline characteristics IMT N (randomized/analyzed): 10/10 Loss to follow‐up or excluded: 0 Age, mean (SD) in years: 58.7 (5.2) Gender (M/F): 6/4 BMI, mean (SD), kg/m²: 24.3 (4.0) Control/sham N (randomized/analyzed): 10/10 Loss to follow‐up or excluded: 0 Age, mean (SD) in years: 60.3 (5.3) Gender (M/F): 5/5 BMI, mean (SD), kg/m²: 24.2 (3.4) Overall N (randomized/analyzed): 20/20 Loss to follow‐up or excluded: 0 Gender (M/F): 11/9 COPD stage (GOLD): moderate to severe Included criteria Required participants to be < 70 years old Moderate to severe non‐reversible airflow obstruction Excluded criteria Exacerbation of COPD within the previous 6 weeks Neoplastic disease or the presence of a disease that could contribute to dyspnea, or exercise limitation (cardiovascular, neuromuscular, or other respiratory diseases) No patients had received treatment with systemic cortisone over the last 6 months
Interventions	Intervention characteristics IMT: performed once/d, 7 d/week, for 8 weeks using Respifit Sdevice (Mauerbach, Australia). The training consisted of strength training at 80% of PImax (≃12 min each session) and endurance training at 60% of PImax (≃ 13.5 min each session) Control/sham: this group did not receive any intervention
Outcomes	Dyspnea: Borg Constant cycle ergometer test Incremental cycle ergometer test Notes: the sensation of dyspnea was assessed every 2 min during exercise Respiratory muscle strength: PImax Respiratory muscle endurance time: Tlim Notes: measured through breathing against 60% PImax Laboratory exercise test: VO2peak (mL/min) Constant cycle ergometer test Incremental cycle ergometer test
Identification	Country: Austria Setting: outpatient clinic Author's name: Milos Petrovic Institution: Pulmonary Department and Karl Landsteiner Institute for Clinical and Experimental Pulmology Email: milos.petrovic@wienkav.at Address: Hietzing Hospital, Wolkensbergenstrasse 1, 1130 Vienna, Austria Clinical trial register: NCT00469313
Notes